Mitsubishi UFJ Financial Group Inc. Common Stock vs Novo Nordisk A/S — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $22.38 (market cap $249.48B), while Novo Nordisk A/S trades at $38.55 (market cap $165.31B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| MUFG | NVO | |
|---|---|---|
Market Cap | $249.48B | $165.31B |
Volume | 4,008,160 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $24.13 | $63.98 |
52-Week Low | $14.62 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $28.96T | $179.56B |
Dividend Yield | 2.4% | 4.71% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →